Abstract
Genome editing has emerged as a powerful tool in research and is entering the stage of therapeutic applications. In the cardiovascular field, its role in basic and translational research is well established. However, biological and technical barriers currently hamper the therapeutic potential of genome editing for cardiovascular diseases. This viewpoint discusses possible routes for promoting therapeutic use of genome editing in the cardiovascular system.
Keywords:
CRISPR; cardiomyopathies; cardiovascular diseases; gene editing; induced pluripotent stem cells.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cardiology / methods*
-
Cardiology / trends
-
Cardiovascular Diseases / genetics
-
Cardiovascular Diseases / therapy*
-
Cells, Cultured
-
Embryonic Stem Cells / transplantation
-
Fibroblasts / physiology
-
Gene Editing / methods*
-
Genome, Human*
-
Humans
-
Induced Pluripotent Stem Cells / transplantation
-
Myocardium / cytology
-
Myocytes, Cardiac / cytology
-
Myocytes, Smooth Muscle / cytology
-
Translational Research, Biomedical / methods
-
Translational Research, Biomedical / trends